Copanlisib

(Aliqopa®)

Copanlisib

Drug updated on 11/13/2023

Dosage FormInjection (intravenous; 60 mg/vial)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.